Form 10|Q for Tscan Therapeutics INC filed 11/12/2024

Form 10-Q for Tscan Therapeutics INC filed 11/12/2024

The condensed consolidated financial statements include the accounts of TScan Therapeutics, Inc. and its subsidiary, TScan Securities. Corporation. All ...

SEC Filings - Investor Relations | TScan Therapeutics, Inc.

November 12, 2024, 8-K · Report of unscheduled material events or corporate event ; November 12, 2024, 10-Q · Quarterly report which provides ...

TScan Therapeutics Reports Third Quarter 2024 Financial Results ...

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ... filings that TScan has made or may make with the SEC in the future.

Form 8-K for Tscan Therapeutics INC filed 11/12/2024

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by ...

TScan Therapeutics, Inc. Common Stock (TCRX) SEC Filings | Nasdaq

Find the latest SEC Filings data for TScan Therapeutics, Inc. Common Stock (TCRX) including 10-K and 10-Q forms at Nasdaq ... 11/12/2024, 09/30/2024.

Form SC 13G/A for Tscan Therapeutics INC filed 11/14/2024

TScan Therapeutics, Inc. (Name of Issuer). Voting Common Stock ... 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES.

TScan Therapeutics Reports Third Quarter 2024 Financial

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on ...

Investor Relations | TScan Therapeutics, Inc.

The Investor Relations website contains information about TScan Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

S-1 - SEC.gov

If this form is filed to register additional securities for an ... TScan,” or “the Company” refer to TScan Therapeutics, Inc. Overview. We are a ...

SEC Filings - Investor Relations | TScan Therapeutics, Inc.

SEC Filings ; March 9, 2022, 10-K · Annual report which provides a comprehensive overview of the company for the past year ; March 8, 2023, 10 ...

Press Releases - Investor Relations | TScan Therapeutics, Inc.

12 Nov '24. TScan Therapeutics Reports Third Quarter 2024 Financial ... 10 months Closed upsized underwritten public offering... Additional Formats.

TScan Therapeutics, Inc. SEC 10-Q Report - TradingView

TScan Therapeutics, Inc., a biotechnology company focused on developing TCR-T therapy candidates for hematologic and solid tumor ...

10-Q | iXBRL Viewer - Investor Relations | TScan Therapeutics, Inc.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 ...

TScan Therapeutics (TCRX) SEC Filings & 10K Form - MarketBeat

11/01/2024 6:00 AM, TScan Therapeutics (Filer), Form 8-K Current report pursuant to Section 13 or 15(d) ; 10/21/2024 3:11 PM, BlackRock, Inc. (Filed by) TScan ...

TScan Therapeutics Announces Closing of Upsized Public Offering

WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ... A registration statement on Form S-3 (File No. 333-277699) ...

TCRX: TScan Therapeutics Inc - Stock Price, Quote and News - CNBC

10 Day Average Volume0.36M; Dividend-; Dividend Yield-; Beta0.83; YTD % Change ... form below. ALL OTHER LOCATIONS: If we do not detect that you are in one ...

10-Q - SEC.gov

Commission File Number: 001-40603. TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter). Delaware. 82-5282075. (State or other ...

TCRX - TScan Therapeutics, Inc. Stock - Stock Price, Institutional ...

Institutional Ownership and Shareholders. TScan Therapeutics, Inc. (US:TCRX) has 152 institutional owners and shareholders that have filed 13D/G or 13F forms ...

Company Presentation - Investor Relations | TScan Therapeutics, Inc.

most recent Annual Report on Form 10-K and any other filings that TScan has ... TScan is a fully integrated, next-generation TCR-T cell therapy company. 3.

TScan Therapeutics, Inc. Common Stock (TCRX) Press Releases

... Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors. May 9, 2024. Show: 10. 10; 25. 1 2 3. Showing 1 - 10 of 23. Quotes.